Taylor Barbara S, Shalev Noga, Wilkin Timothy J
University of Texas Health Science Center, San Antonio, TX, USA.
Columbia University College of Physicians and Surgeons, New York, NY, USA.
Top Antivir Med. 2014 May;22(2):616-31.
The 2014 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted important advances in antiretroviral therapy, with an emphasis on HIV eradication strategies. Follow-up information about the Mississippi baby who remains free of HIV infection off antiretroviral therapy was presented, and a second baby and 1 adult may also have been cured with very early initiation of antiretroviral therapy. The HIV care cascade was again a major focus of the conference. Investigators from around the world presented data on the implementation, and limitations, of the care cascade paradigm. Scale-up of antiretroviral therapy continues and a number of presentations featured optimal ways to measure the impact of these efforts by applying lessons from implementation science and health care economics. Encouraging results from expanded prevention of mother-to-child transmission programs, especially Option B+, were highlighted. Extensive data on transmitted (primary) drug resistance in the United States and Europe were presented.
2014年逆转录病毒与机会性感染会议(CROI)着重介绍了抗逆转录病毒疗法的重要进展,重点是艾滋病毒根除策略。会议展示了有关密西西比婴儿在停止抗逆转录病毒治疗后仍未感染艾滋病毒的后续信息,并且另一名婴儿和一名成人可能也因极早期开始抗逆转录病毒治疗而被治愈。艾滋病毒治疗流程再次成为会议的主要焦点。来自世界各地的研究人员展示了关于治疗流程模式的实施情况及局限性的数据。抗逆转录病毒疗法的推广仍在继续,许多报告介绍了通过应用实施科学和卫生保健经济学的经验教训来衡量这些努力成效的最佳方法。会议强调了扩大预防母婴传播项目(尤其是B+方案)所取得的令人鼓舞的成果。会上还展示了美国和欧洲有关传播性(原发性)耐药性的大量数据。